SCHEMBL4059102

SCHEMBL4059102

Cc1ccc2c(c1)N(c1ccccc1)S(O)(O)N2CCCN(C)C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.40
PDK2 Q15119 1/20 0.35
SLC6A4 P31645 3/20 0.34
HTR2C P28335 2/20 0.34
METAP2 P50579 1/20 0.34
L3MBTL1 Q9Y468 3/20 0.33
GBA1 P04062 1/20 0.33
SLC6A2 P23975 2/20 0.32
CPB2 Q96IY4 1/20 0.31
MAPT P10636 3/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
AAK1 Q2M2I8 1/20 0.31
GPR88 Q9GZN0 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPK1 P28482 1/20 0.31
ATM Q13315 1/20 0.31
F2 P00734 1/20 0.30
GLS O94925 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4939108 0.96 TRPV4 (0.40) TRPV4PDK2SLC6A4HTR2CMETAP2
SCHEMBL4059103 0.91 SLC6A2 (0.41) TRPV4PDK2SLC6A4HTR2CMETAP2
SCHEMBL4939111 0.87 SLC6A2 (0.41) TRPV4PDK2SLC6A4HTR2CMETAP2
SCHEMBL4945111 0.81 SLC6A2 (0.41) TRPV4SLC6A4SLC6A2
SCHEMBL4937965 0.81 SLC6A2 (0.41) TRPV4SLC6A4HTR2CGBA1SLC6A2
SCHEMBL4943918 0.77 SLC6A2 (0.41) TRPV4PDK2SLC6A4HTR2CMETAP2
SCHEMBL4945948 0.77 SLC6A2 (0.41) TRPV4SLC6A4SLC6A2
SCHEMBL4065304 0.75 SIGMAR1 (0.36) SLC6A4HTR2CSLC6A2MAPTLMNA
SCHEMBL4945270 0.75 SLC6A2 (0.39) TRPV4SLC6A4METAP2GBA1SLC6A2
SCHEMBL4052761 0.74 SLC6A2 (0.43) SLC6A4L3MBTL1SLC6A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 TRPV4 1234/4885PDK2 2777/4885SLC6A4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.